An independent systematic review of influenza vaccine evidence published Wednesday in JAMA found that vaccination continues to reduce the risk of severe illness, hospitalization, and death, and that comparative studies turned up no new safety concerns for currently recommended immunizations.
The review was produced by the Vaccine Integrity Project, based at the University of Minnesota's Center for Infectious Disease Research and Policy, in collaboration with the American Medical Association. It was published alongside companion reviews of COVID-19 and RSV immunizations, and an accompanying commentary describing the process.
The reason a private evidence review is carrying this weight is procedural rather than scientific. The federal advisory committee that normally performs this synthesis has not issued 2026-2027 recommendations, and the reviews were commissioned to fill that gap and inform the four societies' recommendations released the same week.
What the Reviewers Examined
The three reviews together identified 299 eligible studies, published primarily between August 2025 and June 2026. Researchers systematically searched major scientific databases for peer-reviewed studies on disease epidemiology and on the effectiveness and safety of immunizations licensed in the United States.
This is an update rather than a fresh start. The project completed a similar review for the 2025-2026 season, which examined a far larger body of literature. This year's effort layers newly published research on top of that foundation, which is why the study count is smaller.
The design matters for how readers should interpret the conclusions. A systematic review synthesizes existing studies; it does not generate new trial data. Most of the underlying evidence on seasonal influenza vaccine effectiveness comes from observational research conducted during real seasons, not from randomized trials of each year's formulation, because reformulating and trialing a vaccine annually against placebo is neither practical nor considered ethical once a benefit is established.
Protection Held, With Real Variation
The central finding is that vaccination remained associated with lower risks of serious illness and influenza-related death.
The more useful finding for households is the qualifier attached to it. Effectiveness varied by season, by age and by risk group. That variation is a genuine feature of influenza vaccines rather than a weakness in the review. Each year's formulation is selected months in advance against a prediction of which strains will circulate, and how closely that prediction matches reality drives much of the year-to-year difference.
What that means in practice is that a flu shot is better understood as a reduction in the odds of a severe outcome than as a guarantee against infection. Someone who gets vaccinated and still catches influenza has not necessarily received a failed product. The clearest and most consistent benefit across the evidence base sits at the severe end: hospitalization and death, rather than mild illness.
Specific figures give that shape. An analysis of network surveillance data found influenza vaccination provided 31 percent protection against influenza-associated hospitalization in older adults. Across eight influenza seasons, vaccine effectiveness against laboratory-confirmed influenza-associated death among children and adolescents was 80 percent. Details on those estimates appear in the evidence review briefing.
The scale of the problem gives that reduction its meaning. Drawing on CDC estimates, the project's respiratory season resources note that influenza was associated with 390,000 to 800,000 hospitalizations during the 2025-2026 season.
The companion reviews produced more specific figures in places. Updated COVID-19 vaccination was 53 percent effective against hospitalization among adults 65 and older during the 2025-2026 season, and vaccination was associated with a 76 percent reduction in COVID-related emergency department visits among children aged 9 months through 4 years.
Reading the Safety Findings Carefully
The safety conclusion was stated as an absence: comparative studies of currently recommended immunizations identified no new safety signals.
That phrasing deserves precision, because it is narrower than no risks. Influenza vaccines have known and documented side effects, including soreness at the injection site, low-grade fever and fatigue, and rare adverse events that appear in existing labeling. A finding of no new signals means that a year of additional published research did not surface a previously unrecognized problem. It does not mean the products carry no risk, and it is not a claim about any individual's experience.
It is also worth noting what the review is and is not. It is an independent synthesis, publicly documented, produced outside the federal process and published in a peer-reviewed journal. It is not a regulatory decision, and it does not itself change what any agency recommends.
From Evidence Review to the Pharmacy Counter
The practical chain runs from these reviews to the recommendations four medical societies issued this week, and from there to a pharmacy or clinic.
Flu vaccination is recommended for everyone 6 months and older under that guidance. Flu and RSV immunizations are already available at major pharmacies, and updated COVID-19 shots have been approved and are reaching shelves.
The cost question looked unsettled a week ago and now looks better. Sarah Nosal, president of the American Academy of Family Physicians, said at a briefing that insurers have indicated to the major medical groups that they will cover this season's respiratory virus immunizations. That is an expressed intention rather than a legal requirement, and coverage rules still key off the federal committee, so calling the plan before booking remains worthwhile.
Several things stay genuinely unresolved. How well this season's formulation matches the strains that actually circulate will not be known until data accumulate over the winter. There is no confirmed date for a federal advisory committee meeting that could produce official 2026-2027 recommendations. And whether every insurer follows through on the coverage indication is untested.
For most people, the takeaway is unremarkable and worth acting on anyway. The evidence continues to support flu vaccination as a way to lower the odds of ending up in a hospital bed; the benefit is largest for older adults, young children, pregnant people and those with chronic conditions; and the reasonable next step is a short conversation with a clinician or pharmacist rather than a search for a definitive percentage.
Key Questions Answered
What was published? A systematic review of influenza vaccine effectiveness and safety for the 2026-2027 season, published in JAMA by the Vaccine Integrity Project with the American Medical Association.
What did it conclude? That vaccination remained associated with lower risks of serious illness and influenza-related death, with effectiveness varying by season, age, and risk group, and that comparative studies found no new safety signals.
Does no new safety signals mean no side effects? No. It means a year of new research did not identify a previously unrecognized problem. Known side effects, mostly mild and short-lived, still apply.
Why does flu vaccine effectiveness vary so much? Each season's formulation is chosen months ahead against a prediction of circulating strains, and the closeness of that match drives much of the year-to-year difference.
Who benefits most? Older adults, young children, pregnant people and people with chronic medical conditions, who carry the highest risk of severe influenza outcomes.
Why did a private group do this review? The federal advisory committee that normally performs it has not issued recommendations for this season, and the reviews were commissioned to inform guidance from medical societies.
Does this change what I should do? Not fundamentally. Flu vaccination is recommended for everyone 6 months and older under this season's society guidance. Confirm coverage with your plan before booking.
